Get started
Author

Jenny Nater

ORCID: 0000-0001-9495-0653
Observed ORCID: 0000-0001-9495-0653
OpenAlex ID: A5089893629
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
2018 · Hui Zhao, John Atkinson, et al. · Cancer Research · 143
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
2024 · Frederick L. Locke, Sattva S. Neelapu, et al. · Transplantation and Cellular Therapy · 35
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
2024 · Olalekan O. Oluwole, Edouard Forcade, et al. · Bone Marrow Transplantation · 31
PDF
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
2025 · Matthew J. Frigault, Ning Yao, et al. · Blood Advances · 18
Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2023 · Michael D. Jain, David B. Miklos, et al. · Clinical Cancer Research · 8
PDF
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
2022 · Olalekan O. Oluwole, Edouard Forcade, et al. · Blood · 6
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
2022 · Armin Ghobadi, Jack H. Landmann, et al. · Blood Advances · 6
Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies
2026 · Shruti Sanjay Salunkhe, Jenny Nater, et al. · Molecular Therapy Advances · 2
Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)
2023 · Mike Mattie, Melanie Grosso, et al. · Blood · 2
PDF
Abstract LB346: Dynamic changes in the tumor microenvironment from initial diagnosis through sequential therapies in patients with large B cell lymphoma undergoing axicabtagene ciloleucel (axi-cel) treatment
2024 · Michael Mattie, Regis Perbost, et al. · Cancer Research · 1
Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Table S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
2025 · Michael D. Jain, David B. Miklos, et al.
PDF
Rapid Increase in Blood CD19 CAR-T Vector Load during the First 5 Days Post Infusion Is Associated with Severe Icans
2025 · Sushma Bharadwaj, Courtney Smith, et al. · Transplantation and Cellular Therapy
Supplementary Table S2 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11
2024 · Michael D. Jain, David B. Miklos, et al.
Supplementary Table S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11
2024 · Michael D. Jain, David B. Miklos, et al.
Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11
2024 · Michael D. Jain, David B. Miklos, et al.
Works count: 77
Citation count: 252
H-index: 6
I10-index: 4
Year
Topic
Type